- Price
- 7.00
- Open
- —
- High
- —
- Low
- —
- Volume
- —
- Currency
- GBX
Delayed data · Source: Aquis Stock Exchange
| 9 Jul 2026 | 07:00:04 | Grant of Incentive Options over Stock |
| 7 Jul 2026 | 07:00:03 | Director's Dealings |
| 29 Jun 2026 | 07:00:11 | Grant of Incentive Options over Stock |
| 26 May 2026 | 07:00:15 | Repayment of Convertible Loan Notes |
| 29 Apr 2026 | 07:00:09 | Update on Share Exchange Agreement |
Cardiogeni Plc is a biotechnology company focused on developing cell therapy medicines for the treatment of heart failure. Its lead product, CLXR-001, is designed for administration during coronary artery bypass surgery. The company operates primarily in the Gulf Cooperation Council (GCC) region, where it is advancing clinical development and commercialization efforts through a joint venture established in the United Arab Emirates. Cardiogeni generates revenue through licensing agreements and aims to secure funding for clinical trials and product development.
| 9 Jul 2026 | 07:00:04 | Grant of Incentive Options over Stock |
| 7 Jul 2026 | 07:00:03 | Director's Dealings |
| 29 Jun 2026 | 07:00:11 | Grant of Incentive Options over Stock |
| 26 May 2026 | 07:00:15 | Repayment of Convertible Loan Notes |
| 29 Apr 2026 | 07:00:09 | Update on Share Exchange Agreement |
Cardiogeni Plc is a biotechnology company focused on developing cell therapy medicines for the treatment of heart failure. Its lead product, CLXR-001, is designed for administration during coronary artery bypass surgery. The company operates primarily in the Gulf Cooperation Council (GCC) region, where it is advancing clinical development and commercialization efforts through a joint venture established in the United Arab Emirates. Cardiogeni generates revenue through licensing agreements and aims to secure funding for clinical trials and product development.